[1] Adarsh V, Lakshmi R. Retroperitoneal liposarcoma: a comprehensive review.[J]. American journal of clinical oncology,2013,12(4):5665-5667.
[2] Park J O, Qin L, Prete F P, et al. Predicting Outcome by Growth Rate of Locally Recurrent Retroperitoneal Liposarcoma[J]. Annals of Surgery,2009,250(6):977-982.
[3] Tyler R, Wanigasooriya K, Taniere P, et al. A review of retroperitoneal liposarcoma genomics[J]. Cancer Treatment Reviews,2020,86:102013.
[4] Trans-Atlantic R S W G. Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG)[J]. Annals of oncology,2018,29(4):857.
[5] Singer S, Antonescu C R, Riedel E, et al. Histologic Subtype and Margin of Resection Predict Pattern of Recurrence and Survival for Retroperitoneal Liposarcoma[J]. Annals of Surgery,2003,121:52-65.
[6] Tan M C B, Brennan M F, Kuk D, et al. Histology-based Classification Predicts Pattern of Recurrence and Improves Risk Stratification in Primary Retroperitoneal Sarcoma[J]. Annals of Surgery,2016,263(3):593-600.
[7] Strauss D C, Hayes A J, Thway K, et al. Surgical management of primary retroperitoneal sarcoma[J]. Br J Surg,2010,97(5):698-706.
[8] Lee S Y, Goh B K P, Teo M C C, et al. Retroperitoneal liposarcomas: the experience of a tertiary Asian center[J]. World journal of surgical oncology,2011,9(1):12.
[9] Tseng W W, Madewell J E, Wei W, et al. Locoregional Disease Patterns in Well-Differentiated and Dedifferentiated Retroperitoneal Liposarcoma: Implications for the Extent of Resection?[J]. Annals of Surgical Oncology,2014,21(7):2136-2143.
[10] Bagaria S P, Gabriel E, Mann G N. Multiply recurrent retroperitoneal liposarcoma[J]. Journal of Surgical Oncology,2018,117(1):62-68.
[11] Smith T E, Lee D, Turner B C, et al. True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management[J]. Int J Radiat Oncol Biol Phys,2000,48(5):1281-1289.
[12] Jo V Y, Fletcher C D M. WHO classification of soft tissue tumors: an update based on the 2013 (4th) edition[J]. Pathology,2014,46(2):95-104.
[13] Ishii K, Yokoyama Y, Nishida Y, et al. Characteristics of primary and repeated recurrent retroperitoneal liposarcoma: outcomes after aggressive surgeries at a single institution[J]. Japanese Journal of Clinical Oncology,2020.
[14] Bartlett E K, Curtin C E, Seier K, et al. Histologic Subtype Defines the Risk and Kinetics of Recurrence and Death for Primary Extremity/Truncal Liposarcoma[J]. Annals of Surgery,2020:1.
[15] Gronchi A, Strauss D C, Miceli R, et al. Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS)[J]. Annals of Surgery,2016,263(5):1002-1009.
[16] Beird H C, Wu C, Ingram D R, et al. Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin[J]. Molecular Case Studies,2018,4(2):a2386.
[17] Thway K. Well-differentiated liposarcoma and dedifferentiated liposarcoma: An updated review[J]. Seminars in Diagnostic Pathology,2019,36(2):112-121.
[18] Sbaraglia M, Dei Tos A P. The pathology of soft tissue sarcomas[J]. La radiologia medica,2019,124(4):266-281.
[19] Jm S, S R, M D, et al. Risk factors of early recurrence in retroperitoneal liposarcoma.[J]. Cirugia espanola,2018,96(9):568-576.
[20] Keung E Z, Hornick J L, Bertagnolli M M, et al. Predictors of Outcomes in Patients with Primary Retroperitoneal Dedifferentiated Liposarcoma Undergoing Surgery[J]. Journal of the American College of Surgeons,2014,218(2):206-217.
[21] Shibata D. Is there a role for incomplete resection in the management of retroperitoneal liposarcomas?[J]. Journal of the American College of Surgeons,2001,193(4):373-379.
[22] Kirane A, Crago A M. The importance of surgical margins in retroperitoneal sarcoma[J]. J Surg Oncol,2016,113(3):270-276.
[23] Wang J, Grignol V P, Gronchi A, et al. Surgical management of retroperitoneal sarcoma and opportunities for global collaboration[J]. Chinese clinical oncology,2018,7(4):39.